RSIP Vision launches AI-based MRI and ultrasound tool

By Leila Hawkins
RSIP Vision's new tool for prostate MRI and ultrasound scans will enable precise navigation during surgery...

RSIP Vision, a leading medical imaging firm, has launched an advanced AI tool for prostate MRI and ultrasound scans. The tool’s fully automated, deep learning-based capabilities uses a registered MRI scan of the prostate to visualise information on top of an ultrasound image, giving surgeons highly accurate, real-time information. 

In prostate-focused procedures, lack of information makes the surgeon’s decision process a challenging task. Research has found that the outcomes of surgical treatment vary widely depending on where and by whom the patient was treated; additionally variation in outcomes can be due to levels of technical skill and the interpretation of the data collected in the operating room. 

Currently, ultrasound alone is commonly used, however certain regions cannot be viewed clearly using just this method. 

Merging MRI and ultrasound

RSIP Vision’s tool can be used in frequent clinical tasks, such as biopsy acquisition and robotic prostate surgeries. During these procedures, MRI information is typically not available due to the complicated nature of its acquisition in real-time. By scanning the patient prior to surgery, it’s possible to merge the MRI image to an ultrasound scan that is acquired during surgery. 

By doing so, the MRI image can be created in real-time, and the regions the surgeon needs to see can be displayed as it would if real-time MRI acquisition were possible. This gives a surgeon many options, such as improved navigation to a tumor during a biopsy.  

Ron Soferman, CEO of RSIP Vision, says that MRI-to-ultrasound technology is an extremely valuable tool for a surgeon to have. "By having RSIP Vision’s new prostate MRI fusion tool at their fingertips, surgeons can avoid damaging sensitive internal structures" he said. 

"Surgeons can also locate clinically relevant regions and reduce procedural risks to patients. Our new tool also cuts down on surgery time, hospitalisation time and overall procedural costs. Most importantly, it gives surgeons the ability to make quick and accurate clinics decisions mid-procedure, alleviating the need to call for higher-level expertise." 

Share

Featured Articles

Health tech leader Philips shares sustainability ambition

Roy Jakobs, Royal Philips CEO, says the health technology company’s sustainability impact plan will ‘enhance accountability & strengthen talent’

Automating gene therapy & pharma discovery at Automata

Sonia Jassi, Drug Discovery & Synthetic Biology Lead at Automata, explains how automation increases efficiency in gene therapy laboratories

Itai Hayut, CEO of Scopio Labs, on AI & blood cancer

Itai Hayut, CEO of healthtech company Scopio Labs, on how AI & digitalisation help in the detection of blood related cancers, anaemia & allergies

2023 predictions with Harshit Jain, global CEO of Doceree

Telehealth & COVID-19

Wolters Kluwer Health: health equity and telehealth

Telehealth & COVID-19

World Mental Health Day: how parents can help stop bullying

Digital Healthcare